Catalent Partners with S.Biomedics on Parkinson’s Stem-Cell Therapy
Event summary
- Catalent and S.Biomedics have partnered to develop and manufacture TED-A9, a stem-cell-derived therapy for Parkinson’s disease.
- TED-A9 is an allogeneic pluripotent stem-cell-derived treatment using S.Biomedics’ proprietary TED platform.
- The partnership aims to support a pivotal U.S. clinical trial (NCT05887466) and future commercialization.
- Catalent will leverage its global network and GMP manufacturing capabilities for scalable production.
The big picture
This partnership underscores the growing collaboration between CDMOs and biotech innovators to accelerate regenerative medicine. Catalent’s expertise in cell therapy manufacturing aligns with S.Biomedics’ ambition to deliver a scalable, commercially viable treatment for Parkinson’s disease. The deal highlights the increasing focus on stem-cell therapies as potential game-changers in neurodegenerative disorders.
What we're watching
- Clinical Progress
- How the Phase 1/2a trial (NCT05887466) advances, as it represents a critical step toward regulatory approval.
- Manufacturing Scale-Up
- Whether Catalent’s GMP-ready manufacturing can meet the demands of global commercialization.
- Competitive Positioning
- The pace at which S.Biomedics can differentiate TED-A9 in a crowded Parkinson’s disease therapy landscape.
Related topics